•
GA
GALT
Galectin Therapeutics Inc.
polygonPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
204.38M
Volume
134.08K
52W High
$7.13
52W Low
$1.12
Open
$3.17
Prev Close
$3.17
Day Range
3.14 - 3.42
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Latest News
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
GlobeNewswire Inc.•Nov 14
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension
GlobeNewswire Inc.•Jun 10
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference
GlobeNewswire Inc.•Jan 10
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
GlobeNewswire Inc.•Aug 13
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
GlobeNewswire Inc.•Jun 4
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
GlobeNewswire Inc.•May 15
Wall Street Breakfast: The Week Ahead
Seeking Alpha•Apr 14
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
GlobeNewswire Inc.•Mar 29